José Baselga

José Baselga (born 3 July 1959) is a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Baselga served as Physician-in-Chief at the Memorial Sloan Kettering Cancer Center until his resignation in September 2018 after it was reported that he had failed to disclose millions of dollars in financial ties with pharmaceutical companies in his research.[1][2][3][4] On January 7, 2019, AstraZeneca announced that they had hired him as head of research and development in oncology.[5]

José Baselga
Born (1959-07-03) 3 July 1959
Barcelona, Spain
NationalitySpanish
Alma mater
Scientific career
FieldsOncology
Institutions

Education and career

Baselga received his MD and PhD degrees from the Autonomous University of Barcelona in 1982. He completed a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center in New York, and subsequently stayed on as a faculty member of its Breast Medicine Service.

From 1996 to 2010, Baselga was the Chairman of the Medical Oncology Service and Founding Director of the recently established Vall d’Hebron Institute of Oncology (VHIO) at the Vall d'Hebron University Hospital in Barcelona. From 2010 to 2012, he was the chief of the Division of Hematology/Oncology and associate director of the MGH Cancer Center in Massachusetts.[6]

He is one of the principal investigators of the Stand Up to Cancer "Dream Team" for "Targeting the PI3K Pathway in Women’s Cancers".[7] He has been involved in the development of several targeted drugs for cancer including cetuximab, pertuzumab, trastuzumab and lapatinib.[8][9]

He was appointed Physician-in-chief at Memorial Sloan Kettering Cancer Center in 2012[10] and was appointed a professor of medicine at Weill Cornell Medical College in 2013.[11]

According to an article in the New York Times published in September 2018, based on investigations done in cooperation with the nonprofit investigative journalism organization ProPublica, Baselga had "failed to disclose millions of dollars in payments from drug and health care companies in recent years, omitting his financial ties from dozens of research articles in prestigious publications like The New England Journal of Medicine and The Lancet.[12][13] Baselga resigned from Memorial Sloan Kettering in response to these articles.[14] He subsequently resigned from the boards of the drug company Bristol-Myers Squibb and the radiation equipment firm Varian Medical Systems.[5] He also resigned from his position as co-editors in chief of the journal Cancer Discovery.[5]

In December 2020, the New York Times reported that "Internal Revenue Service documents showed that the non-profit hospital paid more than $1.5 million in severance to Dr. Baselga in 2018 and 2019." [15]

Honors and awards
  • Young Investigator Award, American Society of Clinical Oncology (ASCO) (1992-1993)[16][17]
  • Career Development Award, American Society of Clinical Oncology (ASCO) (1994-1997)[18]
  • Elected Member, American Society of Clinical Investigation (2004)[19]
  • American Italian Cancer Foundation Prize for Scientific Excellence in Medicine (2007)[20]
  • American Association for Cancer Research-Rosenthal Family Foundation Award (2008)[21]
  • King Jaime I Award in Medical Research, Valencia, Spain (2008)[22]
  • Gold Medal, Queen Sofia Spanish Institute, NY (2010)[23]
  • Joseph B. Martin Award, Massachusetts General Hospital, Boston, MA (2012)[24]
  • Elected Member, National Academy of Medicine (2014)[25]
  • John Wayne Clinical Research Lecture Award, Society of Surgical Oncology (2016)[26]
  • XXVIII Catalonia International Prize (2016)[27]
  • European Society for Medical Oncology Lifetime Achievement Award (2017)[28]

See also

References
  1. "Memorial Sloan Kettering Announces Appointment of New Physician-in-Chief". On Cancer. Memorial Sloan Kettering Cancer Center. September 5, 2012. Retrieved December 8, 2014.
  2. "José Baselga - Memorial Sloan Kettering Cancer Center". www.mskcc.org. Archived from the original on 2015-04-14. Retrieved 2014-08-29.
  3. "The José Baselga Lab - Memorial Sloan Kettering Cancer Center". www.mskcc.org.
  4. nytimes.com 13 September 2018: Top Sloan Kettering Cancer Doctor Resigns After Failing to Disclose Industry Ties
  5. Thomas, Katie; Ornstein, Charles (Jan 7, 2019). "Top Cancer Doctor, Forced Out Over Ties to Drug Makers, Joins Their Ranks". The New York Times. Retrieved Jan 8, 2019.
  6. "José Baselgą M.D". Breastcancer.org. September 17, 2012. Archived from the original on April 20, 2010. Retrieved February 2, 2008.
  7. "Officer Detail".
  8. "Breast Cancer Research Foundation".
  9. "José Baselga". Aura Biosciences.
  10. "Center names physician-in-chief". HemOnc Today. 10 Nov 2012.
  11. "Baselga, Jose". Weill Cornell VIVO. Retrieved 3 April 2017.
  12. Ornstein, Charles; Thomas, Katie (8 September 2018). "Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals". The New York Times. Retrieved 10 September 2018.
  13. Thomas, Katie; Ornstein, Charles (September 9, 2018). "MSK Cancer Center Orders Staff to 'Do a Better Job' of Disclosing Industry Ties". The New York Times.
  14. "Top Breast Cancer Researcher Didn't Disclose Financial Ties". The Scientist Magazine®. Retrieved 14 September 2018.
  15. Thomas, Katie; Ornstein, Charles (December 22, 2020). "Sloan Kettering Paid $1.5 Million Severance to a Cancer Doctor Forced Out Over Conflicts". The New York Times. Retrieved December 22, 2020.
  16. King, Jennifer C.; Lawrence, Theodore S.; Murphy, Sharon B.; Davidson, Nancy E.; Mayer, Robert J. (20 March 2010). "The American Society of Clinical Oncology Cancer Foundation Grants Program: A 25-Year Report and a Look Toward the Future". Journal of Clinical Oncology. 28 (9): 1616–1621. doi:10.1200/JCO.2009.27.4621. PMID 20177012.
  17. "Grant & Award Recipients". Conquer Cancer Foundation. 15 May 2015. Retrieved 23 January 2018.
  18. "Grant & Award Recipients". Conquer Cancer Foundation. 15 May 2015. Retrieved 23 January 2018.
  19. "ASCI - The American Society for Clinical Investigation". www.the-asci.org. Retrieved 21 December 2016.
  20. "Scientific Prize". American-Italian Cancer Foundation. Retrieved 23 January 2018.
  21. "AACR Awards". Oncology Times. 30 (10): 50. May 2008. doi:10.1097/01.COT.0000320584.98431.fa.
  22. "Histórico Premiados Investigación Médica fprj". www.fprj.es (in Spanish). Retrieved 23 January 2018.
  23. "Gold Medal Gala". spanishinstitute.org. Retrieved 6 April 2017.
  24. "Martin Prize Recipients". ecor.mgh.harvard.edu. Retrieved 23 January 2018.
  25. "José Baselga, M.D., Ph.D". National Academy of Medicine. Retrieved 21 December 2016.
  26. "John Wayne Clinical Research Lecturers". www.surgonc.org. Retrieved 23 January 2018.
  27. "Previous winners". Generalitat de Catalunya. Retrieved 23 January 2018.
  28. "ESMO Lifetime Achievement Award | Oncology Awards | ESMO". www.esmo.org. Retrieved 23 January 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.